The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Spero Therapeutics Inc
F:2HA
|
US |
|
C
|
China Mobile Ltd
DUS:CTM
|
CN |
|
Spero Therapeutics Inc
NASDAQ:SPRO
|
US |
|
Jost Werke SE
F:JST
|
DE |
|
M
|
Meituan
SWB:9MD
|
CN |
|
M
|
Memphasys Ltd
ASX:MEM
|
AU |
|
G
|
Golden Agri-Resources Ltd
XMUN:4G3A
|
SG |
|
Caisse regionale de Credit Agricole Mutuel Alpes Provence
PAR:CRAP
|
FR |
|
I
|
International Bancshares Corp
F:IB4
|
US |
|
E
|
ENM Holdings Ltd
F:EMD
|
HK |
|
C
|
Capgemini SE
OTC:CAPMF
|
FR |
|
Prada SpA
F:PRP
|
IT |
|
S
|
Stifel Financial Corp
F:2SI
|
US |
|
D
|
Dillard's Inc
XMUN:DL7A
|
US |
|
AQ Group AB
F:7AQ0
|
SE |
|
Maeda Kosen Co Ltd
TSE:7821
|
JP |
|
T
|
Tocvan Ventures Corp
CNSX:TOC
|
CA |
|
Land and Houses PCL
OTC:LDHOF
|
TH |
|
B
|
Boozt AB
LSE:0RPY
|
SE |
|
S
|
Safestay PLC
SWB:5RI
|
UK |
|
R
|
Red Planet Japan Inc
SWB:DN3
|
JP |
|
Mr Price Group Ltd
OTC:MRPZF
|
ZA |
|
B
|
Boozt AB
SWB:BOK
|
SE |
|
Semight Instruments Co Ltd
SSE:688808
|
CN |
Spero Therapeutics Inc (2HA)’s 12-month stock price forecast through November 2027 has a consensus target of €5.3344, implying 488% upside. The forecast is based on price targets from 5 Wall Street analysts.
Past growth per year Not enough data
Average annual growth cannot be calculated for these periods.
Explore analyst estimates, growth and forecast ranges.
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
According to Wall Street analysts, the average 1-year price target for
2HA is 5.3344 EUR with a low forecast of 3.5214 EUR and a high forecast of 5.4913 EUR.
Over the last 9 years, the compound annual growth rate for Revenue has been 80%. The projected CAGR for the next 3 years is -20%.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Already have an account? Sign in
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more